biotech · Breast Cancer · Pleural carcinosis · SANA
Sana Biotechnology
Sana Biotechnology clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 188 E Blaine St, Suite 400, Seattle, Washington 98102, US
- Founded
- 2018
- Employees
- 265
- Programs
- 19
- Drugs
- 21
- Patents
- 136
Sana Biotechnology projects
9 ClinicalTrials.gov programs sponsored by Sana Biotechnology.
Sana Biotechnology has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ABC2
Sana Biotechnology
Breast Cancer
1 trial -
Dexmedetomidine injection
Sana Biotechnology
Post Spinal Shivering
1 trial -
GN-002
Sana Biotechnology
Parkinson’s Disease
1 trial -
HCQ01
Sana Biotechnology
2019 Novel Coronavirus
2 trials -
Hydroxyurea
Sana Biotechnology
Thalassemia, Beta
1 trial -
Myocet (Non-pegylated liposomal doxorubicin (NPLD))
Sana Biotechnology
Breast Cancer
1 trial -
PITAC_ MaPEPi
Sana Biotechnology
Pleural carcinosis
1 trial -
TREAT LMNA
Sana Biotechnology
Laminopathies
1 trial -
TREDIMIN 25.000 U.I. /2,5 ml soluzione orale
Sana Biotechnology
haematologic condition who need staminal cells transplant
1 trial
Frequently asked questions
How many clinical projects does Sana Biotechnology have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.